Company Description
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound.
The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.
It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
The company has a collaborative research agreement with General Electric Company.
ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Country | United States |
IPO Date | Jun 30, 2017 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 21 |
CEO | Alexander Y. Tokman |
Contact Details
Address: 3600 Green Court Ann Arbor, Michigan United States | |
Website | https://www.endrainc.com |
Stock Details
Ticker Symbol | NDRA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001681682 |
CUSIP Number | 29273B104 |
ISIN Number | US29273B3024 |
Employer ID | 26-0579295 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Alexander Y. Tokman | Acting Chief Executive Officer & Chairman |
Michael Thornton Ph.D. | Chief Technology Officer |
Richard Jacroux | Chief Financial Officer & Secretary |
Dr. Jonathan Behr Ph.D. | Co-Founder |
Steve Freeman | Human Resources Leader |
Ziad Rouag | Head of Regulatory & Clinical Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 22, 2024 | 8-K | Current Report |
Nov 21, 2024 | 10-Q/A | [Amend] Quarterly Report |
Nov 19, 2024 | 10-Q | Quarterly Report |
Nov 15, 2024 | 8-K | Current Report |
Nov 15, 2024 | NT 10-Q | Filing |
Nov 05, 2024 | 8-K | Current Report |
Oct 29, 2024 | 8-K | Current Report |
Sep 17, 2024 | DEFA14A | Filing |
Sep 16, 2024 | DEF 14A | Filing |
Sep 06, 2024 | PRE 14A | Filing |